Table 2

Frequency of Use of Anti-Diabetic Medications
Anti-Diabetic Medications
 Diabetes (N = 55.972)
 Diabetic Neuropathy (N = 2,146)
 Diabetes and Depression (N = 2,379)
 P-Value


N
 %
 N
 %
 N
 %
 DM v DN
 DM v DD
 DN v DD
Sulfonylurea








     Glimepiried
 2,821
 5.04
 180
 8.29
 192
 8.07
 *
 *
 0.8823
     Glipizide
 9,034
 16.14
 458
 21.34
 554
 23.29
 *
 *
 0.1846
     Glyburide
 7,446
 13.30
 451
 21.02
 466
 19.59
 *
 *
 0.3454
     Any Sulfonylurea
 18,207
 32.53
 924
 43.06
 1,072
 45.06
 *
 *
 0.3253
Meglitinide








     Nateglinide
 222
 0.40
 19
 0.89
 6
 0.25
 ***
 0.5252
 ***
     Repaglinide
 863
 1.54
 63
 2.94
 1
 2.27
 *
 ***
 0.1790
     Any Meglitinide
 1,078
 1.93
 82
 3.32
 60
 2.52
 *
 0.1059
 ***
Biguanide








     Metformin HCL
 15,744
 28.13
 952
 44.36
 1,072
 45.06
 *
 *
 0.8625
Thiazolidinedione








     Pioglitazone HCL
 2,371
 4.24
 227
 10.58
 233
 9.79
 *
 *
 0.4238
     Rosiglitazone Maleate
 3,073
 5.49
 287
 13.37
 292
 12.27
 *
 *
 0.2650
     Any Thiazolidinedione
 5,283
 9.44
 491
 22.88
 494
 20.77
 *
 *
 ***
Alpha Glucose Inhibitor








     Acarbose
 256
 0.46
 13
 0.61
 18
 0.76
 0.5883
 0.0939
 0.7412
     Miglitol
 112
 0.20
 13
 0.61
 1
 0.04
 **
 0.2222
 *
     Any Alpha Glucose Inhibitor
 363
 0.65
 26
 1.21
 19
 0.80
 ***
 0.6553
 0.2072
Insulin








     Insulin Glargine
 272
 0.49
 68
 3.17
 75
 3.15
 *
 *
 0.9976
     Insulin Lispro
 2,837
 5.07
 469
 21.85
 359
 15.09
 *
 *
 *
     Any Insulin
 2,940
 5.25
 493
 22.97
 381
 16.02
 *
 *
 *

*P-value ≤ 0.0001; **P-value ≤ 0.001; ***P-value ≤ 0.05.

P values based on Tukey-Kramer method to adjust for multiple comparisons.

Le et al. Cost Effectiveness and Resource Allocation 2006 4:18   doi:10.1186/1478-7547-4-18

Open Data